Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530756 | 0.91 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC18A2MTNR1ANQO2 | |
| SCHEMBL4615995 | 0.77 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC18A2SSTR2SSTR4 | |
| SCHEMBL4616463 | 0.77 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC18A2SSTR2SSTR4 | |
| SCHEMBL4615998 | 0.77 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC18A2SSTR2SSTR4 | |
| SCHEMBL2689256 | 0.77 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC18A2SSTR2SSTR4 | |
| SCHEMBL8267196 | 0.76 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC18A2SSTR2SSTR4 | |
| SCHEMBL7050745 | 0.70 | SLC6A2 (0.63) | SLC6A4SLC6A2SLC18A2SSTR2SSTR4 | |
| SCHEMBL5530774 | 0.69 | SLC6A4 (0.77) | SLC6A4SLC6A2 | |
| SCHEMBL5534081 | 0.69 | SLC6A2 (0.68) | SLC6A4SLC6A2 | |
| SCHEMBL5830749 | 0.69 | BCHE (0.61) | SLC6A4SLC6A2SLC18A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | GAP43, SLC18A2, CHRNA6 | SLC6A4 104/4885SLC6A2 47/4885SLC18A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.